PloS one · 2026
Comparative outcomes of PreserFloTMMicroShunt in primary open-angle and pseudoexfoliative glaucoma: A matched analysis.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bourauel Leonie, Aretz Benjamin, Petrak Michael, Holz Frank G, Mercieca Karl, Liegl Constance
Аннотация
PURPOSE: Comparing outcomes of PreserFloTM MicroShunt in eyes with primary open-angle (POAG) and pseudoexfoliative glaucoma (PEXG) through a matched analysis.
METHODS: Retrospective matched-pair analysis of patients undergoing PreserFloTM MicroShunt (PFMS) due to POAG (n = 25) and PEXG (n = 25). Success rates (A/B: IOP ≤ 21 / 18 mmHg + IOP reduction ≥20% from baseline; C: IOP ≤ 15 mmHg + IOP reduction ≥25%; D: IOP ≤ 12 mmHg + IOP reduction ≥30%) and secondary outcomes were evaluated.
RESULTS: Fifty eyes of 49 patients were included. At 12 months, complete and qualified success rates for Criteria A - D were 68.0% and 96.0%, 68.0% and 96.0%, 64.0% and 72.0%, and 32.0% and 32.0%, respectively, in the POAG group, compared with 44.0% and 76.0%, 40.0% and 72.0%, 32.0% and 52.0%, and 8.0% and 12.0%, respectively, in the PEXG group (p = 0.039, 0.024, 0.189, and 0.271, respectively). Mean preoperative IOP decreased from 25.12 mmHg (POAG) and 25.64 mmHg (PEXG, p = 0.98) to 12.64 mmHg and 15.04 mmHg postoperatively (p = 0.043). The mean number of IOP-lowering drops was significantly lower in eyes with POAG (0.52 ± 1.01) than with PEXG (1.3 ± 1.55; p = 0.031) after 12 months. Eyes with PEXG had significantly higher rates of postoperative complications than eyes with POAG (p = 0.038) with no vision-threatening sequelae.
CONCLUSIONS: PFMS is a safe and effective procedure for reducing IOP in eyes with POAG and PEXG, with lower IOP levels being achieved in eyes with POAG. Significantly more postoperative complications and interventions were needed in eyes with PEXG.
METHODS: Retrospective matched-pair analysis of patients undergoing PreserFloTM MicroShunt (PFMS) due to POAG (n = 25) and PEXG (n = 25). Success rates (A/B: IOP ≤ 21 / 18 mmHg + IOP reduction ≥20% from baseline; C: IOP ≤ 15 mmHg + IOP reduction ≥25%; D: IOP ≤ 12 mmHg + IOP reduction ≥30%) and secondary outcomes were evaluated.
RESULTS: Fifty eyes of 49 patients were included. At 12 months, complete and qualified success rates for Criteria A - D were 68.0% and 96.0%, 68.0% and 96.0%, 64.0% and 72.0%, and 32.0% and 32.0%, respectively, in the POAG group, compared with 44.0% and 76.0%, 40.0% and 72.0%, 32.0% and 52.0%, and 8.0% and 12.0%, respectively, in the PEXG group (p = 0.039, 0.024, 0.189, and 0.271, respectively). Mean preoperative IOP decreased from 25.12 mmHg (POAG) and 25.64 mmHg (PEXG, p = 0.98) to 12.64 mmHg and 15.04 mmHg postoperatively (p = 0.043). The mean number of IOP-lowering drops was significantly lower in eyes with POAG (0.52 ± 1.01) than with PEXG (1.3 ± 1.55; p = 0.031) after 12 months. Eyes with PEXG had significantly higher rates of postoperative complications than eyes with POAG (p = 0.038) with no vision-threatening sequelae.
CONCLUSIONS: PFMS is a safe and effective procedure for reducing IOP in eyes with POAG and PEXG, with lower IOP levels being achieved in eyes with POAG. Significantly more postoperative complications and interventions were needed in eyes with PEXG.